Pub. Date : 2003
PMID : 12904090
14 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Insulin glargine: an updated review of its use in the management of diabetes mellitus. | Insulin Glargine | insulin | Homo sapiens |
| 2 | Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. | Insulin Glargine | insulin | Homo sapiens |
| 3 | Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. | Insulin Glargine | insulin | Homo sapiens |
| 4 | Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from which small amounts of insulin glargine are gradually released. | Insulin Glargine | insulin | Homo sapiens |
| 5 | The plasma concentration versus time profile of insulin glargine is therefore relatively constant in relation to conventional human insulins, with no pronounced peak over 24 hours. | Insulin Glargine | insulin | Homo sapiens |
| 6 | Early randomised trials with insulin glargine generally showed greater reductions in fasting blood or plasma glucose levels and a reduced frequency of nocturnal hypoglycaemia relative to neutral protamine Hagedorn (NPH) insulin in patients with type 1 diabetes mellitus. | Insulin Glargine | insulin | Homo sapiens |
| 7 | More recent data with insulin glargine have included evidence of improved glycaemic control, with improvements in satisfaction with treatment over NPH insulin. | Insulin Glargine | insulin | Homo sapiens |
| 8 | Results from comparative studies and meta-analyses in individuals with type 2 diabetes show lower incidences of nocturnal hypoglycaemia with insulin glargine than with NPH insulin, with two studies showing a significantly greater improvement in glycosylated haemoglobin levels with insulin glargine than with NPH. | Insulin Glargine | insulin | Homo sapiens |
| 9 | Results from comparative studies and meta-analyses in individuals with type 2 diabetes show lower incidences of nocturnal hypoglycaemia with insulin glargine than with NPH insulin, with two studies showing a significantly greater improvement in glycosylated haemoglobin levels with insulin glargine than with NPH. | Insulin Glargine | insulin | Homo sapiens |
| 10 | Long-term data show maintenance of glycaemic control with insulin glargine for up to 39 months in adults and children with type 1 and adults with type 2 diabetes. | Insulin Glargine | insulin | Homo sapiens |
| 11 | In conclusion, insulin glargine is an effective and well tolerated basal insulin therapy when given as a single daily subcutaneous injection to patients with diabetes, with benefits in terms of glycaemic control and reduced frequency of hypoglycaemia over regimens based on conventional basal insulins. | Insulin Glargine | insulin | Homo sapiens |
| 12 | In conclusion, insulin glargine is an effective and well tolerated basal insulin therapy when given as a single daily subcutaneous injection to patients with diabetes, with benefits in terms of glycaemic control and reduced frequency of hypoglycaemia over regimens based on conventional basal insulins. | Insulin Glargine | insulin | Homo sapiens |
| 13 | Accumulating data and official recommendations show the suitability of insulin glargine for first-line use in selected patients with type 2 diabetes who require insulin treatment, as well as in patients with type 1 disease, and confirm its use in children and adolescents. | Insulin Glargine | insulin | Homo sapiens |
| 14 | Accumulating data and official recommendations show the suitability of insulin glargine for first-line use in selected patients with type 2 diabetes who require insulin treatment, as well as in patients with type 1 disease, and confirm its use in children and adolescents. | Insulin Glargine | insulin | Homo sapiens |